AIM/HYPOTHESIS: Cellular cholesterol efflux to plasma is important in reverse cholesterol transport and may be affected by simvastatin in type 1 diabetes mellitus. METHODS: In 14 moderately hypercholesterolaemic type 1 diabetic and 13 healthy men we determined plasma (apo)lipoproteins, pre-beta HDL formation, cholesteryl ester transfer protein (CETP) activity, phospholipid transfer protein (PLTP) activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux out of Fu5AH cells and fibroblasts. After diet run-in, diabetic patients were randomly treated with simvastatin 10, 20, 40 mg and placebo, once daily each, for 6 weeks in a double-blind crossover design. RESULTS:Plasma very low density lipid protein (VLDL)+LDL cholesterol, LDL cholesterol, HDL phospholipids, apolipoprotein (apo) A-I, apo B, CETP activity, PLTP activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux from Fu5AH cells and fibroblasts were higher in diabetic patients. Pre-beta HDL formation was unaltered. Simvastatin treatment decreased VLDL+LDL cholesterol, LDL cholesterol, triglycerides and apo B, CETP activity, cholesterol esterification and cholesteryl ester transfer. HDL cholesterol increased and its change was correlated with the change in cholesteryl ester transfer. The ability to promote cholesterol efflux from Fu5AH cells and fibroblasts did not change after simvastatin. CONCLUSIONS/ INTERPRETATION: The capacity of plasma from moderately hypercholesterolaemic type 1 diabetic patients to induce cholesterol efflux out of Fu5AH cells and fibroblasts is enhanced, probably due to higher apo A-I, HDL phospholipids and PLTP activity. Simvastatin increases HDL cholesterol in type 1 diabetic patients via lowering of plasma cholesteryl ester transfer. The HDL changes after simvastatin do not increase cellular cholesterol efflux further.
RCT Entities:
AIM/HYPOTHESIS: Cellular cholesterol efflux to plasma is important in reverse cholesterol transport and may be affected by simvastatin in type 1 diabetes mellitus. METHODS: In 14 moderately hypercholesterolaemic type 1 diabetic and 13 healthy men we determined plasma (apo)lipoproteins, pre-beta HDL formation, cholesteryl ester transfer protein (CETP) activity, phospholipid transfer protein (PLTP) activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux out of Fu5AH cells and fibroblasts. After diet run-in, diabeticpatients were randomly treated with simvastatin 10, 20, 40 mg and placebo, once daily each, for 6 weeks in a double-blind crossover design. RESULTS: Plasma very low density lipid protein (VLDL)+LDL cholesterol, LDL cholesterol, HDL phospholipids, apolipoprotein (apo) A-I, apo B, CETP activity, PLTP activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux from Fu5AH cells and fibroblasts were higher in diabeticpatients. Pre-beta HDL formation was unaltered. Simvastatin treatment decreased VLDL+LDL cholesterol, LDL cholesterol, triglycerides and apo B, CETP activity, cholesterol esterification and cholesteryl ester transfer. HDL cholesterol increased and its change was correlated with the change in cholesteryl ester transfer. The ability to promote cholesterol efflux from Fu5AH cells and fibroblasts did not change after simvastatin. CONCLUSIONS/ INTERPRETATION: The capacity of plasma from moderately hypercholesterolaemic type 1 diabeticpatients to induce cholesterol efflux out of Fu5AH cells and fibroblasts is enhanced, probably due to higher apo A-I, HDL phospholipids and PLTP activity. Simvastatin increases HDL cholesterol in type 1 diabeticpatients via lowering of plasma cholesteryl ester transfer. The HDL changes after simvastatin do not increase cellular cholesterol efflux further.
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: S S Soedamah-Muthu; H M Colhoun; M J Thomason; D J Betteridge; P N Durrington; G A Hitman; J H Fuller; K Julier; M I Mackness; H A W Neil Journal: Atherosclerosis Date: 2003-04 Impact factor: 5.162
Authors: Mark A Sarzynski; Jonathan J Ruiz-Ramie; Jacob L Barber; Cris A Slentz; John W Apolzan; Robert W McGarrah; Melissa N Harris; Timothy S Church; Mark S Borja; Yumin He; Michael N Oda; Corby K Martin; William E Kraus; Anand Rohatgi Journal: Arterioscler Thromb Vasc Biol Date: 2018-02-08 Impact factor: 8.311
Authors: Ana C Lo Prete; Clederson H Dina; Carolina H Azevedo; Camila G Puk; Neuza H M Lopes; Whady A Hueb; Raul Cavalcante Maranhão Journal: Lipids Date: 2009-09-16 Impact factor: 1.880
Authors: Mohamad O Ahmed; Rachel E Byrne; Agnieszka Pazderska; Ricardo Segurado; Weili Guo; Anjuli Gunness; Isolda Frizelle; Mark Sherlock; Khalid S Ahmed; Anne McGowan; Kevin Moore; Gerard Boran; Fiona C McGillicuddy; James Gibney Journal: Diabetologia Date: 2020-11-09 Impact factor: 10.122
Authors: Evgenia Gourgari; Martin P Playford; Umberto Campia; Amit K Dey; Fran Cogen; Stephanie Gubb-Weiser; Mihriye Mete; Sameer Desale; Maureen Sampson; Allen Taylor; Kristina I Rother; Alan T Remaley; Nehal N Mehta Journal: Cardiovasc Diabetol Date: 2018-12-19 Impact factor: 9.951